Showing results (1-10 of 3,074) with videos related to

Sort By:
Pageof 308
Fibrogenesis & Tissue Repair|August 3, 2012
Diabetic angiopathy and angiogenic defectsLing Xu, Keizo Kanasaki, Munehiro Kitada, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|October 19, 2012
Pathophysiology of the aging kidney and therapeutic interventionsKeizo Kanasaki, Munehiro Kitada, Daisuke Koya
World Journal of Diabetes|June 18, 2014
Clinical therapeutic strategies for early stage of diabetic kidney diseaseMunehiro Kitada, Keizo Kanasaki, Daisuke Koya
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 8, 2013
The biological consequence of obesity on the kidneyKeizo Kanasaki, Munehiro Kitada, Megumi Kanasaki, et al.
Clinical and Experimental Nephrology|November 14, 2013
Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathyDaisuke Koya, Munehiro Kitada, Shinji Kume, et al.
Molecular Medicine Reports|July 5, 2011
Reversal of redox-dependent inhibition of diacylglycerol kinase by antioxidants in mesangial cells exposed to high glucoseHisanari Atsumi, Munehiro Kitada, Keizo Kanasaki, et al.
Biochemical and Biophysical Research Communications|September 22, 2012
SIRT1 inactivation induces inflammation through the dysregulation of autophagy in human THP-1 cellsAi Takeda-Watanabe, Munehiro Kitada, Keizo Kanasaki, et al.
Fibrogenesis & Tissue Repair|December 1, 2011
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsMegumi Kanasaki, Takako Nagai, Munehiro Kitada, et al.
Archives of Pharmacal Research|January 31, 2013
Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathyShinji Kume, Munehiro Kitada, Keizo Kanasaki, et al.
Frontiers in Pharmacology|May 1, 2014
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetesKeizo Kanasaki, Takako Nagai, Kyoko Nitta, et al.
Pageof 308